Metabolic effects of newly synthesized phosphodiesterase-3 inhibitor 6-[4-(4-methylpiperidin-1-yl)-4-oxobutoxy]-4-methylquinolin-2(1H)-one on rat adipocytes.

Abstract

BACKGROUND:

Clinical use of selective PDE3 inhibitors as cardiotonic agents is limited because of their chronotropic and lipolytic side effects. In our previous work, we synthesized a new PDE3 inhibitor named MC2 (6-[4-(4-methylpiperidin-1-yl)-4-oxobutoxy]-4-methylquinolin-2(1H)-one) which produced a high positive inotropic action with a negative chronotropic effect. This work was done to evaluate the effects of MC2 on adipocytes and compare its effects with those of amrinone and cilostamide.

METHODS:

Preadipocytes were isolated from rat adipose tissue and differentiated to adipocyte in the presence of cilostamide, amrinone or MC2. Lipolysis and adipogenesis was evaluated by measuring glycerol level and Oil Red O staining, respectively. Adipocyte proliferation and apoptosis were determined with MTT assay and Annexin V/PI staining, respectively.

RESULTS:

Differentiation to adipocyte was induced by amrinone but not by cilostamide or MC2. Basal and isoproterenol-stimulated lipolysis significantly increased by cilostamide (p<0.05). Similarly, amrinone enhanced the stimulated lipolysis (p<0.01). On the other hand, MC2 significantly decreased both adipogenesis (p<0.05) and stimulated lipolysis (p<0.001). Also, incubation of differentiated adipocytes with MC2 caused the loss of cell viability, which was associated with the elevation in apoptotic rate (p<0.05).

CONCLUSION:

Our data indicate that selective PDE3 inhibitors produce differential effects on adipogenesis and lipolysis. MC2 has proapoptotic and antilipolytic effects on adipocytes and does not stimulate adipogenesis. Therefore, in comparison with the clinically available selective PDE3 inhibitors, MC2 has lowest metabolic side effects and might be a good candidate for treatment of congestive heart failure.

• Authors: Bagher Alinejad, Reza Shafiee-Nick, Hamid Sadeghian, Ahmad Ghorbani
• Journal: Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences (Daru) Vol. 23 Pg. 19 (Feb 21 2015) ISSN: 2008-2231 [Electronic] Switzerland
• PMID: 25880831 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• 6-(4-(4-methylpiperidin-1-yl)-4-oxobutoxy)-4-methylquinolin-2(1H)-one
• Phosphodiesterase 3 Inhibitors
• Piperidines
• Quinolones
• cilostamide

Topics

• Adipocytes (drug effects, physiology)
• Adipogenesis (drug effects)
• Animals
• Apoptosis
• Cell Differentiation
• Cell Survival (drug effects)
• Cells, Cultured
• Lipolysis (drug effects)
• Male
• Phosphodiesterase 3 Inhibitors (chemical synthesis, pharmacology)
• Piperidines (chemical synthesis, pharmacology)
• Quinolones (chemical synthesis, pharmacology)
• Rats
• Rats, Wistar